NanaBidial (NanoCelle CBD)

CLINICAL TRIAL

The buccal administration of a nanocelleTM CBD preparation to healthy volunteers: a safety, tolerability and pharmacokinetic exploratory pilot study.

FORMULATION

NanaBidialTM is an investigative new product containing approximately 18:1 ratio of Cannabidiol (CBD) and delta-9-trethydrocannabinol (THC), in a sub-micron spray applied to the oro-buccal membrane.

DATE of HREC approval

31/08/18

HREC

National Institute of Integrative Medicine (NIIM) EC00436

HREC Approval ID

0049E_2018

CTN

CT‐2017‐CTN‐01923‐1 v4

ANZCTR

ACTRN12617001491358

STUDY SITE

Scientia Clinical Research, Level 5, Bright Building, Corner High and Avoca Street, Randwick NSW 2031 Australia.

STATUS

Completed